Hypertriglyceridemic pancreatitis subphenotypes and differential responses to low-molecular-weight heparin: analyses from a cohort and a randomized controlled trial.
Ling Ding, Zichen Wang, Yuning Wang et al.
✦ AI-curated · Sources linked
In 30 seconds
This study identified two distinct subphenotypes of hypertriglyceridemic pancreatitis (HTG-AP) in a cohort of 1483 patients and validated these findings in a randomized controlled trial with 533 participants. The subphenotypes exhibited different responses to low-molecular-weight heparin (LMWH), with phenotype 2 showing a relative risk of 0.57 for new-onset organ failure and/or mortality compared to phenotype 1's risk of 1.04.
Key findings
- Phenotype 1 included 76.5% of patients, while phenotype 2 comprised 23.5%.
- Patients in phenotype 2 had significantly worse outcomes, including persistent organ failure and higher mortality (all P < 0.001).
- In the RCT, LMWH plus insulin reduced the risk of organ failure/mortality in phenotype 2 (RR 0.57) compared to phenotype 1 (RR 1.04).
- The interaction between treatment effect and subphenotype was significant (P = 0.04 unadjusted, 0.01 adjusted).
Why it matters
Understanding the subphenotypes of HTG-AP can help clinicians tailor treatment strategies, potentially improving outcomes for patients with this heterogeneous condition. Identifying which patients may benefit from specific interventions is crucial for effective management.